Page last updated: 2024-10-27

fluoxetine and Obesity

fluoxetine has been researched along with Obesity in 118 studies

Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.

Obesity: A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).

Research Excerpts

ExcerptRelevanceReference
"This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo."9.12An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007)
"These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain."9.10Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002)
"The effects of fluoxetine on food intake, body weight, and mood of obese individuals was examined in a 16-week inpatient/outpatient study."9.09Fluoxetine-maintained obese humans: effect on food intake and body weight. ( Comer, SD; Fischman, MW; Foltin, RW; Haney, M; Ward, AS, 1999)
"To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration."9.09Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999)
"Fluoxetine is effective, well tolerated and relatively safe in the short-term treatment of obesity in the Taiwanese population when added to a low calorie diet."9.08Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet. ( Chian, CY; Huang, CC; Lin, JD, 1998)
"Fluoxetine improves insulin-mediated glucose disposal in obese patients with NIDDM independently of weight loss."9.08Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997)
"Our study aims at assessing the efficacy and safety of fluoxetine as compared with placebo in the treatment of obesity using a double-blind crossover design."9.08Comparison of fluoxetine and placebo in the treatment of obesity. ( Barredo-Acedo, F; Escobar-Jiménez, F; Fernández-Soto, ML; González-Jiménez, A; Luna del Castillo, JD, 1995)
"We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking."9.08Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995)
"The effect of fluoxetine on body weight and spontaneous food choice was studied in twenty-three healthy, non-depressed, obese females on an outpatient basis."9.07Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity. ( Koppeschaar, HP; Meinders, AE; Op de Kamp, I; Pijl, H; Veldhuis, HD; Willekens, FL, 1991)
"Fluoxetine hydrochloride (Lovan, Eli Lilly and Company, Indianapolis, Indiana, USA), a specific serotonin uptake inhibitor, was compared with placebo in 458 obese outpatients in a 52-week double-blind randomized ten-site trial to study its effect on weight reduction."9.07Fluoxetine: a randomized clinical trial in the treatment of obesity. ( Enas, GG; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1994)
" To demonstrate the use of this methodology, we applied the criteria in an analysis of eight randomized, double-blind controlled trials comparing fluoxetine (n = 522) with placebo (n = 504) for weight loss."9.07Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. ( Atkinson, RL; Goldstein, DJ; Roback, PJ; Sayler, ME, 1994)
" Fluoxetine, an inhibitor of serotonin reuptake, decreases food intake in animals and is associated with weight loss in depressed and otherwise healthy obese patients."9.06Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). ( Byyny, RL; Dauer, AD; Enas, GG; Kirby, RW; Kreindler, TG; Levine, LR; Levy, B; Lucas, CP; McIlwain, HH; Thompson, WL, 1989)
"Fluoxetine is a highly specific serotonin reuptake inhibitor."7.77Clinical studies with fluoxetine in obesity. ( Wise, SD, 1992)
"Fluoxetine, a serotonin re-uptake inhibitor with antidepressive and appetite reduction effects, could improve insulin sensitivity."7.69[The effect of fluoxetine on insulin resistance in non diabetic obese patients]. ( Aguirre, C; Araya, V; Contreras, P; Depix, MS; Zura, ML, 1995)
"Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e."6.71Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005)
"Fluoxetine (F) is a specific serotonin-reuptake inhibitor that has been shown to promote weight loss and improve glycemic control in obese diabetic patients."6.68Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. ( Astrup, A; Bak, JF; Bjerre, U; Breum, L; Jacobsen, S, 1995)
"Obesity is a major health care concern because of its associated medical complications and increased mortality."6.68Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success. ( Goldstein, DJ; Hamilton, SH; Rampey, AH; Roback, PJ; Sayler, ME; Tollefson, GD; Wilson, MG, 1995)
"Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss."6.67Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993)
"Fluoxetine is a specific inhibitor of serotonin re-uptake with very minimal affinity for serotonergic or other receptors."6.66Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity. ( Bosomworth, J; Levine, LR; Rosenblatt, S, 1987)
"Hypogonadotropic hypogonadism is a major characteristic of patients with PWS, and it is speculated to be due to hypothalamic insufficiency."5.29Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine. ( Clayton, AH; O'Donnell, T; Shaw, HA; Warnock, JK, 1995)
"Fluoxetine treatment of mice restricted to 3."5.28Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice. ( Dubuc, PU; Peterson, CM, 1990)
" The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated."5.27Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987)
"To compare the efficacy and safety of diethylpropion (DEP), fenproporex (FEN), mazindol (MZD), fluoxetine (FXT) and sibutramine (SIB) in promoting weight loss."5.19A comparative study of five centrally acting drugs on the pharmacological treatment of obesity. ( Boguszewski, CL; Cunha, DR; do Desterro de Figueiredo, M; dos Santos, CM; Radominski, R; Suplicy, H, 2014)
"This open-label pilot study of combination therapy of metformin and fluoxetine gave encouraging weight reduction, and these results suggest the need for a randomized double-blind clinical trial comparing the two components and the combination to placebo."5.12An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction. ( Amini, M; Aminorroaya, A; Dastjerdi, MS; Kazemi, F; Mohammady, M; Najafian, A, 2007)
"These results suggest that fluoxetine coadministration is clinically ineffective and cannot attenuate olanzapine-induced weight gain."5.10Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition. ( Fuchs, C; Gil-Ad, I; Maayan, R; Pashinian, A; Poyurovsky, M; Schneidman, M; Weizman, A, 2002)
"To evaluate the weight reducing effect of fluoxetine on steroid-induced obesity, we conducted an open, clinical intervention study of 20-40 mg/day fluoxetine, 24 weeks duration."5.09Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients. ( Achiron, A; Barak, Y; Noy, S; Pinhas-Hamiel, O, 1999)
"The effects of fluoxetine on food intake, body weight, and mood of obese individuals was examined in a 16-week inpatient/outpatient study."5.09Fluoxetine-maintained obese humans: effect on food intake and body weight. ( Comer, SD; Fischman, MW; Foltin, RW; Haney, M; Ward, AS, 1999)
"Our study aims at assessing the efficacy and safety of fluoxetine as compared with placebo in the treatment of obesity using a double-blind crossover design."5.08Comparison of fluoxetine and placebo in the treatment of obesity. ( Barredo-Acedo, F; Escobar-Jiménez, F; Fernández-Soto, ML; González-Jiménez, A; Luna del Castillo, JD, 1995)
"We tested whether 14 wk of dexfenfluramine (30 mg) or fluoxetine (40 mg) treatment would prevent weight gain after subjects quit smoking."5.08Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation. ( el-Khoury, A; Goldberg, H; McDermott, J; Pingitore, R; Spring, B; Wurtman, J; Wurtman, R, 1995)
"Fluoxetine improves insulin-mediated glucose disposal in obese patients with NIDDM independently of weight loss."5.08Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss. ( Bourque, J; Chiasson, JL; Ducros, F; Garon, J; Maheux, P, 1997)
" To demonstrate the use of this methodology, we applied the criteria in an analysis of eight randomized, double-blind controlled trials comparing fluoxetine (n = 522) with placebo (n = 504) for weight loss."5.07Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data. ( Atkinson, RL; Goldstein, DJ; Roback, PJ; Sayler, ME, 1994)
"Fluoxetine, an inhibitor of serotonin re-uptake, has been shown to cause weight loss in humans and animals."5.07Fluoxetine treatment of the obese diabetic. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992)
"Fluoxetine hydrochloride (Lovan, Eli Lilly and Company, Indianapolis, Indiana, USA), a specific serotonin uptake inhibitor, was compared with placebo in 458 obese outpatients in a 52-week double-blind randomized ten-site trial to study its effect on weight reduction."5.07Fluoxetine: a randomized clinical trial in the treatment of obesity. ( Enas, GG; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1994)
"Suicidality data from 11 double-blind controlled trials in the United States Investigational New Drug fluoxetine obesity clinical trial data base (3819 randomized outpatients) were reviewed."5.07Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction. ( Beasley, CM; Goldstein, DJ; Masica, DN; Potvin, JH; Rampey, AH, 1993)
"To determine whether fluoxetine is effective in the long-term treatment of obesity and whether it is particularly useful in the treatment of obese binge-eaters, the authors randomly assigned 45 obese subjects (22 with binge-eating problems and 23 without binge-eating) to fluoxetine (60 mg/day) or placebo in a 52-week double-blind trial."5.06A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters. ( Ewing, L; Gooding, W; Kern, E; Marcus, MD; McDermott, M; Wing, RR, 1990)
" Fluoxetine, an inhibitor of serotonin reuptake, decreases food intake in animals and is associated with weight loss in depressed and otherwise healthy obese patients."5.06Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub). ( Byyny, RL; Dauer, AD; Enas, GG; Kirby, RW; Kreindler, TG; Levine, LR; Levy, B; Lucas, CP; McIlwain, HH; Thompson, WL, 1989)
"Fluoxetine, orlistat, and sibutramine can achieve statistically significant weight loss over 12 to 57 weeks."4.82Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus. ( Avenell, A; Gregg, E; Lau, J; Norris, SL; Schmid, CH; Zhang, X, 2005)
" Survival analysis was performed using Cox proportional hazards regression models and visualized using Kaplan Meier survival curves, with the following covariates-sex, ethnicity, smoking history, fluoxetine use, obesity, diabetes mellitus, and hypertension."4.31Effect of statins on the age of onset of age-related macular degeneration. ( Chiang, JN; Corradetti, G; Ganesh, D; Halperin, E; Sadda, SR; Zaitlen, N, 2023)
" We aimed to investigate the relationships among body weight, body mass index (BMI=kg/m(2)), change in a depression rating scale, and change in a functional scale with fluoxetine treatment for hospitalized patients with major depressive disorder (MDD)."3.80Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder. ( Chen, CC; Lin, CH; McIntyre, RS; Wong, J, 2014)
"Fluoxetine is a highly specific serotonin reuptake inhibitor."3.77Clinical studies with fluoxetine in obesity. ( Wise, SD, 1992)
"Chronic fluoxetine administration in obese Zucker rats generated a reduction in body weight gain, food intake, adipocyte size, fat mass, and body protein."3.71Effects of fluoxetine administration on neuropeptide y and orexins in obese zucker rat hypothalamus. ( Abecia, LC; Casis, L; Echevarría, E; Gutiérrez, A; Macarulla, MT; Portillo, MP; Rodríguez, VM; Saracíbar, G, 2002)
" They also had mature onset obesity characterized by a dramatic 80-150% increase in body weight, increased linear growth, and elevated serum levels of leptin, insulin, glucose, and cholesterol."3.71Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity. ( Bates, B; Fan, G; Fekete, C; Jaenisch, R; Kelly, J; Kuehn, R; Lechan, RM; Rios, M, 2001)
" To illustrate an application of this method, we used data from 1,026 patients completing at least 6 months of double-blind therapy in clinical trials comparing fluoxetine (N=522) with placebo (N=504) for weight loss."3.69Baseline predictors of success when comparing two treatments. ( Goldstein, DJ; Rampey, AH; Roback, PJ; Wilson, MG, 1994)
"Serotonin reuptake inhibitors, such as fluoxetine, fenfluramine, and dexfenfluramine, are frequently used to treat obesity, depression, and bulimia."3.69Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study. ( Boyd, LD; Dwyer, JT; Papas, A, 1997)
"Fluoxetine, a serotonin re-uptake inhibitor with antidepressive and appetite reduction effects, could improve insulin sensitivity."3.69[The effect of fluoxetine on insulin resistance in non diabetic obese patients]. ( Aguirre, C; Araya, V; Contreras, P; Depix, MS; Zura, ML, 1995)
"Sertraline has been studied less extensively, and there have been a few studies concerning SSRIs that report follow-up data at more than 12 weeks of follow-up."2.73A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder. ( Brustolin, A; Campisi, S; Fassino, S; Lavagnino, L; Leombruni, P; Pierò, A, 2008)
"Treatment with olanzapine may impact a patient's weight; thus, long-term weight gain and potential predictors (e."2.71Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder. ( Andersen, SW; Clemow, DB; Corya, SA, 2005)
" FL did not affect thermic response to oral glucose neither after acute nor chronic administration (p=NS for all groups studied)."2.69Metabolic effects of fluoxetine in obese menopausal women. ( Bertolini, M; Bondi, M; Del Rio, G; Menozzi, R; Venneri, MG, 2000)
"Fluoxetine (F) is a specific serotonin-reuptake inhibitor that has been shown to promote weight loss and improve glycemic control in obese diabetic patients."2.68Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. ( Astrup, A; Bak, JF; Bjerre, U; Breum, L; Jacobsen, S, 1995)
"Obesity is a major health care concern because of its associated medical complications and increased mortality."2.68Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success. ( Goldstein, DJ; Hamilton, SH; Rampey, AH; Roback, PJ; Sayler, ME; Tollefson, GD; Wilson, MG, 1995)
"Fluoxetine treatment produced a significant weight loss of 1."2.68Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects. ( Blundell, JE; Hill, AJ; Lawton, CL; Wales, JK, 1995)
"Weight reduction is essential in the management of most non-insulin-dependent diabetics, but this therapeutical goal is difficult to obtain."2.68Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study. ( Daubresse, JC; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1996)
"After treatment, weight loss (on average) was observed in both groups: -2."2.67The effect of fluoxetine on body weight, body composition and visceral fat accumulation. ( Koppeschaar, HP; Seidell, JC; Smits, P; Visser, M, 1993)
"Fluoxetine is an antidepressant drug with weight reducing properties."2.67An assessment of the thermogenic effects of fluoxetine in obese subjects. ( Andrews, JF; Murphy, CM; Stinson, JC; Tomkin, GH, 1992)
"Body weight was kept constant."2.67Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients. ( Frölich, M; Krans, HM; Meinders, AE; Potter van Loon, BJ; Radder, JK; Zwinderman, AH, 1992)
"Fluoxetine is an inhibitor of serotonin re-uptake which has been found to produce weight loss in humans and animals."2.67A randomized double-blind clinical trial of fluoxetine in obese diabetics. ( Bray, GA; Devine, W; Fujioka, K; Gray, DS, 1992)
"When nondiabetics and NIDDM were considered together, only the most insulin-resistant individuals demonstrated a decrease in ED50pgu (P less than 0."2.67Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals. ( Frölich, M; Krans, HM; Meinders, AE; Potter van Loon, BJ; Radder, JK; Zwinderman, AH, 1992)
"Weight loss was significantly higher in the fluoxetine-treated patients, whose diabetic status improved."2.67Fluoxetine therapy in obese diabetic and glucose intolerant patients. ( Daubresse, JC; Friedman, H; Kolanowski, J; Krzentowski, G; Kutnowski, M; Scheen, A; Van Gaal, L, 1992)
"Fluoxetine 60 mg/day was effective for a longer period than fluoxetine 20 mg/day or placebo in maintaining weight loss."2.67Fluoxetine: a randomized clinical trial in the maintenance of weight loss. ( Dornseif, BE; Fludzinski, LA; Goldstein, DJ; Levine, LR; Potvin, JH; Rampey, AH, 1993)
"Obesity is a major cause of increased morbidity and mortality among patients with PWS."2.44[Therapeutical approach of obesity in Prader-Willi Syndrome]. ( Almeida, MQ; Carvalho, DF; Cercato, C; Halpern, A; Mancini, MC, 2007)
"Obesity is associated with considerable morbidity and decreased life expectancy."2.41Options for pharmacological management of obesity in patients treated with atypical antipsychotics. ( Sanders, TA; Taylor, D; Werneke, U, 2002)
"Because obesity is a risk factor for numerous medical disorders and excess mortality, it is imperative that effective treatments be developed."2.40Challenges in obesity management. ( Borrell, L; Foreyt, JP; Haddock, CK; Poston, WS, 1998)
"A number of symptoms associated with eating disorders overlap those of depression and OCD, suggesting a theoretical and practical case for evaluating the SSRIs in the treatment of anorexia nervosa, bulimia nervosa, binge-eating disorder, and obesity."2.40The use of selective serotonin reuptake inhibitors in eating disorders. ( Mayer, LE; Walsh, BT, 1998)
"Obesity is a major risk factor for morbidity and mortality, and a series of pharmacologic approaches are available for helping to manage the problem."2.40The pharmacologic approach to the treatment of obesity. ( Abdeen, MA; Frishman, WH; Michaelson, MD; Weiser, M, 1997)
"Fluoxetine has a nonlinear pharmacokinetic profile."2.39Clinical pharmacokinetics of fluoxetine. ( Altamura, AC; Moro, AR; Percudani, M, 1994)
"The resultant weight loss is variable and there appears to be no way of predicting good responders, nor is there evidence that additional weight loss attributable to drug therapy is sustained once treatment is discontinued, although nonpharmacological strategies for preventing weight regain are worthy of exploration."2.38Appraisal of the clinical value of serotoninergic drugs. ( Hodge, J; Munro, JF; Scott, C, 1992)
" We aimed to characterise the prevalence and seriousness of adverse drug events (ADEs) related to anti-obesity medications and to identify predictors associated with increased risk of serious adverse events (SAE), thereby conveying evidence on drug safety."1.91A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication. ( Choi, CY; Choi, YJ; Kim, CU; Shin, S, 2023)
"Fluoxetine was the reference treatment option in the medication models."1.39Influence of body mass index on the choice of therapy for depression and follow-up care. ( Arterburn, D; Bogart, A; Boudreau, DM; Haneuse, S; Simon, G; Theis, MK; Westbrook, E, 2013)
"Fluoxetine was used to block the 5-HT reuptake transporter (SERT), and the levels of mRNA for tryptophan hydroxylase 1 and SERT were determined by quantitative PCR, and SERT protein was determined by Western blot."1.38Serotonin availability in rat colon is reduced during a Western diet model of obesity. ( Bertrand, PP; Bertrand, RL; Chen, H; Howitt, L; Liu, L; Murphy, TV; Sandow, SL; Senadheera, S; Tan, KL; Tanoto, A, 2012)
"Because obesity can affect catecholaminergic signaling, we determined the effects of i."1.34Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice. ( Billes, SK; Cowley, MA, 2007)
"Leptin is a permissive metabolic signal for reproduction, but GnRH neurons do not appear to express leptin receptors, suggesting that interneurons transmit leptin signals to these cells."1.31Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction? ( Clayton, AH; Howard, LC; Moenter, SM; Sullivan, SD, 2002)
"Obesity is one of the pathologies with ever-increasing prevalence in modern societies."1.31[The role of pharmacotherapy for treatment of obesity in adults]. ( Czupryniak, L; Drzewoski, J, 2000)
"Hypogonadotropic hypogonadism is a major characteristic of patients with PWS, and it is speculated to be due to hypothalamic insufficiency."1.29Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine. ( Clayton, AH; O'Donnell, T; Shaw, HA; Warnock, JK, 1995)
"Fluoxetine treatment of mice restricted to 3."1.28Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice. ( Dubuc, PU; Peterson, CM, 1990)
" The adverse event profile in obese patients, though differing slightly from that seen in depressed patients, was similar in that events observed were generally mild and well tolerated."1.27Safety of fluoxetine in the treatment of obesity. ( Zerbe, RL, 1987)

Research

Studies (118)

TimeframeStudies, this research(%)All Research%
pre-19907 (5.93)18.7374
1990's58 (49.15)18.2507
2000's38 (32.20)29.6817
2010's12 (10.17)24.3611
2020's3 (2.54)2.80

Authors

AuthorsStudies
Serralde-Zuñiga, AE1
González-Garay, AG1
Rodríguez-Carmona, Y1
Meléndez-Mier, G1
Ganesh, D1
Chiang, JN1
Corradetti, G1
Zaitlen, N1
Halperin, E1
Sadda, SR1
Choi, YJ1
Choi, CY1
Kim, CU1
Shin, S1
Scabia, G1
Barone, I1
Mainardi, M1
Ceccarini, G1
Scali, M1
Buzzigoli, E1
Dattilo, A1
Vitti, P1
Gastaldelli, A1
Santini, F1
Pizzorusso, T1
Maffei, L1
Maffei, M1
da Silva, AI1
Braz, GRF1
Silva, SCA1
Pedroza, AADS1
de Lima-Júnior, NC1
Silva, TLA1
Lagranha, CJ1
Lee, SH1
Mastronardi, CA1
Li, RW1
Paz-Filho, G1
Dutcher, EG1
Lewis, MD1
Vincent, AD1
Smith, PN1
Bornstein, SR1
Licinio, J1
Wong, ML1
Boudreau, DM1
Arterburn, D4
Bogart, A1
Haneuse, S1
Theis, MK1
Westbrook, E1
Simon, G1
Suplicy, H1
Boguszewski, CL1
dos Santos, CM1
do Desterro de Figueiredo, M1
Cunha, DR1
Radominski, R1
Lin, CH1
Chen, CC1
Wong, J1
McIntyre, RS1
France, M1
Skorich, E1
Kadrofske, M1
Swain, GM1
Galligan, JJ1
Leombruni, P1
Pierò, A1
Lavagnino, L1
Brustolin, A1
Campisi, S1
Fassino, S1
Zarate, J4
Churruca, I5
Pascual, J1
Casis, L5
Sallés, J2
Echevarría, E6
López de Jesús, M1
Saenz del Burgo, L2
Downe, KA1
Goldfein, JA2
Devlin, MJ2
Ayala, ME1
Rezvanian, H1
Hashemipour, M1
Kelishadi, R1
Tavakoli, N1
Poursafa, P1
Ariturk, Z1
Alici, H1
Cakici, M1
Davutoglu, V1
Bertrand, RL1
Senadheera, S1
Tanoto, A1
Tan, KL1
Howitt, L1
Chen, H1
Murphy, TV1
Sandow, SL1
Liu, L1
Bertrand, PP1
Grilo, CM2
Crosby, RD1
Wilson, GT2
Masheb, RM2
Kumar, J1
Chuang, JC1
Na, ES1
Kuperman, A1
Gillman, AG1
Mukherjee, S1
Zigman, JM1
McClung, CA1
Lutter, M1
Werneke, U1
Taylor, D1
Sanders, TA1
Epling, J1
Weng, CS1
Hung, YL1
Shyu, LY1
Chang, YH1
Papakostas, GI1
Petersen, T1
Iosifescu, DV1
Burns, AM1
Nierenberg, AA1
Alpert, JE1
Rosenbaum, JF1
Fava, M1
Maina, G1
Albert, U1
Salvi, V1
Bogetto, F1
Shekelle, PG1
Morton, SC1
Maglione, M1
Suttorp, M1
Tu, W1
Li, Z1
Maggard, M1
Mojica, WA1
Shugarman, L1
Solomon, V1
Portillo, MP4
Gutiérreza, A1
Macarulla, MT4
Norris, SL1
Zhang, X1
Avenell, A1
Gregg, E1
Schmid, CH1
Lau, J1
Compton, R1
Spiller, HA1
Bosse, GM1
DeLaet, D1
Flum, D1
Molinari, E1
Baruffi, M1
Croci, M1
Marchi, S1
Petroni, ML1
Goldstein, DJ8
Rampey, AH6
Dornseif, BE1
Levine, LR4
Potvin, JH4
Fludzinski, LA2
Roback, PJ3
Wilson, MG3
Visser, M2
Seidell, JC2
Koppeschaar, HP6
Smits, P2
Andersen, SW1
Clemow, DB1
Corya, SA1
Zumalabe, JM1
Billes, SK1
Cowley, MA1
Dastjerdi, MS1
Kazemi, F1
Najafian, A1
Mohammady, M1
Aminorroaya, A1
Amini, M1
Whigham, LD1
Dhurandhar, NV1
Rahko, PS1
Atkinson, RL2
Guimarães, C1
Pereira, LR1
Iucif Júnior, N1
Cesarino, EJ1
de Almeida, CA1
de Carvalho, D1
Queiroz, RH1
Toubro, S1
Carvalho, DF1
Cercato, C1
Almeida, MQ1
Mancini, MC1
Halpern, A1
Aylwin, S1
Al-Zaman, Y1
Gutiérrez, A2
Fernández-Soto, ML1
González-Jiménez, A1
Barredo-Acedo, F1
Luna del Castillo, JD1
Escobar-Jiménez, F1
Mendoza Espejo, R1
Díaz Pérez de Madrid, J1
Buitrago, F1
Warnock, JK1
Clayton, AH2
Shaw, HA1
O'Donnell, T1
Spring, B1
Wurtman, J1
Wurtman, R1
el-Khoury, A1
Goldberg, H1
McDermott, J1
Pingitore, R1
Barak, Y2
Lampl, Y1
Achiron, A2
Sarova-Pinhas, I1
Elizur, A1
Connolly, VM1
Gallagher, A1
Kesson, CM1
Gray, DS3
Bross, R1
Hoffer, LJ1
Sayler, ME3
Holman, SL1
Enas, GG3
Altamura, AC1
Moro, AR1
Percudani, M1
Pijl, H4
Cohen, AF1
Iestra, JA1
Schoemaker, HC1
Frölich, M4
Onkenhout, W1
Meinders, AE7
Lamberto, M1
Novi, RF1
Mantovan, M1
Masica, DN1
Beasley, CM2
Tollefson, GD2
Fawcett, J1
Winokur, G1
Faries, DE1
Willekens, FL2
Lawton, CL1
Wales, JK1
Hill, AJ1
Blundell, JE1
Araya, V1
Contreras, P1
Aguirre, C1
Depix, MS1
Zura, ML1
Hamilton, SH1
Dryden, S2
Frankish, HM1
Wang, Q1
Pickavance, L1
Williams, G2
Greeno, CG1
Wing, RR2
Breum, L1
Bjerre, U1
Bak, JF1
Jacobsen, S1
Astrup, A1
Jordaan, GP1
Roberts, MC1
Emsley, RA1
Daubresse, JC2
Kolanowski, J2
Krzentowski, G2
Kutnowski, M2
Scheen, A2
Van Gaal, L2
Maheux, P1
Ducros, F1
Bourque, J1
Garon, J1
Chiasson, JL1
Anchors, M1
Weiser, M1
Frishman, WH1
Michaelson, MD1
Abdeen, MA1
Jackson, HC1
Needham, AM1
Hutchins, LJ1
Mazurkiewicz, SE1
Heal, DJ1
Boyd, LD1
Dwyer, JT1
Papas, A1
Huang, CC1
Chian, CY1
Lin, JD1
Poston, WS1
Foreyt, JP1
Borrell, L1
Haddock, CK1
Mayer, LE1
Walsh, BT1
Noy, S1
Pinhas-Hamiel, O1
Cowley, G1
Springen, K1
Ward, AS1
Comer, SD1
Haney, M1
Fischman, MW1
Foltin, RW1
Brown, M1
King, P1
Bondi, M1
Menozzi, R1
Bertolini, M1
Venneri, MG1
Del Rio, G1
Carino, JS1
Wolk, SL1
Voznesenskaia, TG1
Safonova, VA1
Platonova, NM1
Czupryniak, L1
Drzewoski, J1
Dursun, SM1
Devarajan, S1
Rios, M1
Fan, G1
Fekete, C1
Kelly, J1
Bates, B1
Kuehn, R1
Lechan, RM1
Jaenisch, R1
Sullivan, SD1
Howard, LC1
Moenter, SM1
Poyurovsky, M1
Pashinian, A1
Gil-Ad, I1
Maayan, R1
Schneidman, M1
Fuchs, C1
Weizman, A1
Saracíbar, G1
Rodríguez, VM1
Abecia, LC1
Potter van Loon, BJ2
Radder, JK2
Krans, HM2
Zwinderman, AH2
Fujioka, K2
Devine, W2
Bray, GA2
Stinson, JC1
Murphy, CM1
Andrews, JF1
Tomkin, GH1
Kopelman, PG1
Elliott, MW1
Simonds, A1
Cramer, D1
Ward, S1
Wedzicha, JA1
Friedman, H1
Op de Kamp, I1
Veldhuis, HD1
Wise, SD1
Munro, JF1
Scott, C1
Hodge, J1
Darga, LL1
Carroll-Michals, L1
Botsford, SJ1
Lucas, CP2
Zelissen, PM1
Dubuc, PU1
Peterson, CM1
Marcus, MD1
Ewing, L1
Kern, E1
McDermott, M1
Gooding, W1
Thompson, WL1
Byyny, RL1
Dauer, AD1
Kirby, RW1
Kreindler, TG1
Levy, B1
McIlwain, HH1
Kinney-Parker, JL1
Smith, D1
Ingle, SF1
Ferguson, JM2
Feighner, JP1
Rosenblatt, S1
Bosomworth, J1
Zerbe, RL1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Do Visuals of Symptom Change Increase Rates of Rapid Response in First Weeks of CBT for Eating Disorders?[NCT02940613]80 participants (Anticipated)Interventional2016-12-31Active, not recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

20 reviews available for fluoxetine and Obesity

ArticleYear
Use of Fluoxetine to Reduce Weight in Adults with Overweight or Obesity: Abridged Republication of the Cochrane Systematic Review.
    Obesity facts, 2022, Volume: 15, Issue:4

    Topics: Adult; Body Mass Index; Fluoxetine; Humans; Obesity; Overweight; Systematic Reviews as Topic

2022
Options for pharmacological management of obesity in patients treated with atypical antipsychotics.
    International clinical psychopharmacology, 2002, Volume: 17, Issue:4

    Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones;

2002
Pharmacological and surgical treatment of obesity.
    Evidence report/technology assessment (Summary), 2004, Issue:103

    Topics: Adult; Appetite Depressants; Bupropion; Cyclobutanes; Diethylpropion; Fluoxetine; Fructose; Gastric

2004
Obesity.
    Clinical evidence, 2003, Issue:10

    Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; O

2003
Obesity.
    Clinical evidence, 2004, Issue:11

    Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Humans; Lactones; Mazindol; O

2004
Pharmacotherapy for weight loss in adults with type 2 diabetes mellitus.
    The Cochrane database of systematic reviews, 2005, Jan-25, Issue:1

    Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Fluoxetin

2005
Obesity.
    Clinical evidence, 2005, Issue:13

    Topics: Adult; Appetite Depressants; Cyclobutanes; Diethylpropion; Fluoxetine; Gastric Bypass; Gastroplasty;

2005
[Therapeutical approach of obesity in Prader-Willi Syndrome].
    Arquivos brasileiros de endocrinologia e metabologia, 2007, Volume: 51, Issue:6

    Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Child; Child, Preschool; Female; Fluoxetine; Fru

2007
Emerging concepts in the medical and surgical treatment of obesity.
    Frontiers of hormone research, 2008, Volume: 36

    Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Baria

2008
Clinical pharmacokinetics of fluoxetine.
    Clinical pharmacokinetics, 1994, Volume: 26, Issue:3

    Topics: Administration, Oral; Aged; Aging; Biological Availability; Dose-Response Relationship, Drug; Drug I

1994
Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
    Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists, 1993, Volume: 5, Issue:4

    Topics: Antidepressive Agents, Tricyclic; Bulimia; Clinical Trials as Topic; Depressive Disorder; Double-Bli

1993
Adverse event frequencies generate hypotheses of efficacy and safety.
    Clinical pharmacology and therapeutics, 1993, Volume: 54, Issue:3

    Topics: Drug-Related Side Effects and Adverse Reactions; Fluoxetine; Humans; Obesity; Placebos; Randomized C

1993
The pharmacologic approach to the treatment of obesity.
    Journal of clinical pharmacology, 1997, Volume: 37, Issue:6

    Topics: Adrenergic beta-Agonists; Appetite Depressants; Cardiovascular Diseases; Cyclobutanes; Energy Metabo

1997
Challenges in obesity management.
    Southern medical journal, 1998, Volume: 91, Issue:8

    Topics: 1-Naphthylamine; Adrenergic beta-Agonists; Appetite Depressants; Behavior Therapy; Caffeine; Cyclobu

1998
The use of selective serotonin reuptake inhibitors in eating disorders.
    The Journal of clinical psychiatry, 1998, Volume: 59 Suppl 15

    Topics: Anorexia Nervosa; Antidepressive Agents; Bulimia; Clinical Trials as Topic; Combined Modality Therap

1998
Clinical studies with fluoxetine in obesity.
    The American journal of clinical nutrition, 1992, Volume: 55, Issue:1 Suppl

    Topics: Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Weight Loss

1992
Appraisal of the clinical value of serotoninergic drugs.
    The American journal of clinical nutrition, 1992, Volume: 55, Issue:1 Suppl

    Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Obesity; Serotonin; Weight Loss

1992
Very low calorie diets and recently developed anti-obesity drugs for treating overweight in non-insulin-dependent diabetics.
    The Netherlands journal of medicine, 1990, Volume: 37, Issue:3-4

    Topics: Adrenergic beta-Agonists; Diabetes Mellitus, Type 2; Diet, Reducing; Fenfluramine; Fluoxetine; Human

1990
[Regulation of food intake and the treatment of obesity using centrally-active serotonergic drugs].
    Nederlands tijdschrift voor geneeskunde, 1991, Apr-20, Volume: 135, Issue:16

    Topics: Adult; Energy Intake; Energy Metabolism; Female; Fenfluramine; Fluoxetine; Humans; Male; Middle Aged

1991
Fluoxetine and weight: something lost and something gained?
    Clinical pharmacy, 1989, Volume: 8, Issue:10

    Topics: Appetite; Fluoxetine; Humans; Obesity

1989

Trials

51 trials available for fluoxetine and Obesity

ArticleYear
A comparative study of five centrally acting drugs on the pharmacological treatment of obesity.
    International journal of obesity (2005), 2014, Volume: 38, Issue:8

    Topics: Adult; Amphetamines; Anti-Obesity Agents; Body Mass Index; Brazil; Cyclobutanes; Diet, Reducing; Die

2014
A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder.
    Progress in neuro-psychopharmacology & biological psychiatry, 2008, Aug-01, Volume: 32, Issue:6

    Topics: Adult; Body Mass Index; Bulimia Nervosa; Double-Blind Method; Female; Fluoxetine; Humans; Middle Age

2008
Restraint, hunger, and disinhibition following treatment for binge-eating disorder.
    The International journal of eating disorders, 2009, Volume: 42, Issue:6

    Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Body Mass Index; Bulimia Nervosa; Cognitive B

2009
A randomized, triple masked, placebo-controlled clinical trial for controlling childhood obesity.
    World journal of pediatrics : WJP, 2010, Volume: 6, Issue:4

    Topics: Adolescent; Child; Drug Therapy, Combination; Female; Fluoxetine; Humans; Male; Metformin; Obesity

2010
12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder.
    Journal of consulting and clinical psychology, 2012, Volume: 80, Issue:6

    Topics: Adolescent; Adult; Binge-Eating Disorder; Cognitive Behavioral Therapy; Combined Modality Therapy; D

2012
Obesity among outpatients with major depressive disorder.
    The international journal of neuropsychopharmacology, 2005, Volume: 8, Issue:1

    Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depr

2005
Weight gain during long-term treatment of obsessive-compulsive disorder: a prospective comparison between serotonin reuptake inhibitors.
    The Journal of clinical psychiatry, 2004, Volume: 65, Issue:10

    Topics: Adult; Ambulatory Care; Citalopram; Clomipramine; Female; Fluoxetine; Fluvoxamine; Follow-Up Studies

2004
Binge eating disorder in obesity: comparison of different therapeutic strategies.
    Eating and weight disorders : EWD, 2005, Volume: 10, Issue:3

    Topics: Adult; Aged; Body Mass Index; Bulimia Nervosa; Cognitive Behavioral Therapy; Cohort Studies; Combine

2005
Fluoxetine: a randomized clinical trial in the maintenance of weight loss.
    Obesity research, 1993, Volume: 1, Issue:2

    Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Carbohydrates; Cholesterol; Cholesterol, LDL;

1993
No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity.
    Obesity research, 1994, Volume: 2, Issue:2

    Topics: Abdominal Fat; Adult; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Body Weight; Double-Blind

1994
Long-term weight gain in patients treated with open-label olanzapine in combination with fluoxetine for major depressive disorder.
    The Journal of clinical psychiatry, 2005, Volume: 66, Issue:11

    Topics: Adult; Ambulatory Care; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Depressive Disorder,

2005
Rapid response to treatment for binge eating disorder.
    Journal of consulting and clinical psychology, 2006, Volume: 74, Issue:3

    Topics: Adolescent; Adult; Bulimia Nervosa; Cognitive Behavioral Therapy; Double-Blind Method; Female; Fluox

2006
An open-label pilot study of the combination therapy of metformin and fluoxetine for weight reduction.
    International journal of obesity (2005), 2007, Volume: 31, Issue:4

    Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Drug Therapy, Combination; Female;

2007
Tolerability and effectiveness of fluoxetine, metformin and sibutramine in reducing anthropometric and metabolic parameters in obese patients.
    Arquivos brasileiros de endocrinologia e metabologia, 2006, Volume: 50, Issue:6

    Topics: Adolescent; Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Appetite Depressa

2006
Comparison of fluoxetine and placebo in the treatment of obesity.
    Annals of nutrition & metabolism, 1995, Volume: 39, Issue:3

    Topics: Adult; Cross-Over Studies; Double-Blind Method; Female; Fluoxetine; Humans; Obesity; Selective Serot

1995
[Effectiveness of serotonergic agonists in the treatment of obese patients].
    Atencion primaria, 1995, Oct-15, Volume: 16, Issue:6

    Topics: Adult; Appetite Depressants; Body Mass Index; Diet, Reducing; Female; Fenfluramine; Fluoxetine; Foll

1995
Efficacies of dexfenfluramine and fluoxetine in preventing weight gain after smoking cessation.
    The American journal of clinical nutrition, 1995, Volume: 62, Issue:6

    Topics: Adult; Analysis of Variance; Appetite Depressants; Body Mass Index; Dietary Carbohydrates; Dietary P

1995
A study of fluoxetine in obese elderly patients with type 2 diabetes.
    Diabetic medicine : a journal of the British Diabetic Association, 1995, Volume: 12, Issue:5

    Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Evaluation S

1995
Fluoxetine increases resting energy expenditure and basal body temperature in humans.
    The American journal of clinical nutrition, 1995, Volume: 61, Issue:5

    Topics: Adult; Body Temperature; Chemotherapy, Adjuvant; Diet, Reducing; Double-Blind Method; Energy Metabol

1995
Evaluating success of weight loss programs, with an application to fluoxetine weight reduction clinical trial data.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1994, Volume: 18, Issue:11

    Topics: Adolescent; Adult; Aged; Combined Modality Therapy; Diet, Reducing; Double-Blind Method; Female; Flu

1994
Pattern analysis method for assessing successful weight reduction.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1994, Volume: 18, Issue:5

    Topics: Adult; Aged; Blood Pressure; Confidence Intervals; Counseling; Diabetes Mellitus, Type 2; Double-Bli

1994
Fluoxetine: a randomized clinical trial in the treatment of obesity.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1994, Volume: 18, Issue:3

    Topics: Adult; Body Mass Index; Double-Blind Method; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity;

1994
Evidence for brain serotonin-mediated control of carbohydrate consumption in normal weight and obese humans.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1993, Volume: 17, Issue:9

    Topics: Adult; Amino Acids; Analysis of Variance; Appetite Regulation; Blood Glucose; Brain; Diet; Dietary C

1993
Analyses of suicidality in double-blind, placebo-controlled trials of pharmacotherapy for weight reduction.
    The Journal of clinical psychiatry, 1993, Volume: 54, Issue:8

    Topics: Adolescent; Adult; Aged; Ambulatory Care; Benzphetamine; Body Mass Index; Comorbidity; Depressive Di

1993
The effect of fluoxetine on body weight, body composition and visceral fat accumulation.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1993, Volume: 17, Issue:5

    Topics: Abdomen; Adipose Tissue; Adult; Body Composition; Double-Blind Method; Fluoxetine; Humans; Magnetic

1993
Serotoninergic manipulation, meal-induced satiety and eating pattern: effect of fluoxetine in obese female subjects.
    Obesity research, 1995, Volume: 3, Issue:4

    Topics: Adult; Body Weight; Cross-Over Studies; Dietary Carbohydrates; Dietary Fats; Double-Blind Method; Ea

1995
Efficacy and safety of long-term fluoxetine treatment of obesity--maximizing success.
    Obesity research, 1995, Volume: 3 Suppl 4

    Topics: Double-Blind Method; Fluoxetine; Humans; Obesity; Placebos; Risk Factors; Selective Serotonin Reupta

1995
A double-blind, placebo-controlled trial of the effect of fluoxetine on dietary intake in overweight women with and without binge-eating disorder.
    The American journal of clinical nutrition, 1996, Volume: 64, Issue:3

    Topics: Adult; Affect; Appetite; Double-Blind Method; Energy Intake; Feeding and Eating Disorders; Female; F

1996
Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity.
    Metabolism: clinical and experimental, 1995, Volume: 44, Issue:12

    Topics: Adult; Blood Glucose; Body Composition; Diabetes Mellitus, Type 2; Female; Fluoxetine; Glucose Intol

1995
Usefulness of fluoxetine in obese non-insulin-dependent diabetics: a multicenter study.
    Obesity research, 1996, Volume: 4, Issue:4

    Topics: Adolescent; Adult; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dou

1996
Fluoxetine improves insulin sensitivity in obese patients with non-insulin-dependent diabetes mellitus independently of weight loss.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1997, Volume: 21, Issue:2

    Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluoxetine

1997
Short-term treatment of obesity with fluoxetine as a supplement to a low calorie diet.
    Changgeng yi xue za zhi, 1998, Volume: 21, Issue:1

    Topics: Adult; Diet, Reducing; Energy Intake; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Select

1998
Fluoxetine treatment for weight reduction in steroid-induced obesity: a pilot study in myasthenia gravis patients.
    European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology, 1999, Volume: 9, Issue:1-2

    Topics: Adult; Anti-Inflammatory Agents; Antidepressive Agents, Second-Generation; Body Mass Index; Female;

1999
Fluoxetine-maintained obese humans: effect on food intake and body weight.
    Physiology & behavior, 1999, Volume: 66, Issue:5

    Topics: Adult; Affect; Analysis of Variance; Body Weight; Eating; Female; Fluoxetine; Humans; Male; Obesity;

1999
Metabolic effects of fluoxetine in obese menopausal women.
    Journal of endocrinological investigation, 2000, Volume: 23, Issue:5

    Topics: Antidepressive Agents, Second-Generation; Blood Glucose; Body Temperature Regulation; Double-Blind M

2000
Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy.
    The International journal of eating disorders, 2000, Volume: 28, Issue:3

    Topics: Adult; Appetite Depressants; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug Therapy,

2000
Olanzapine-induced weight gain in patients with first-episode schizophrenia: a double-blind, placebo-controlled study of fluoxetine addition.
    The American journal of psychiatry, 2002, Volume: 159, Issue:6

    Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Drug Therapy, Co

2002
Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin-dependent diabetic individuals.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1992, Volume: 16, Issue:2

    Topics: C-Peptide; Diabetes Mellitus, Type 2; Double-Blind Method; Female; Fluoxetine; Glucose; Humans; Insu

1992
Fluoxetine treatment of the obese diabetic.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1992, Volume: 16, Issue:3

    Topics: Adult; Blood Glucose; Chemotherapy, Adjuvant; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blin

1992
An assessment of the thermogenic effects of fluoxetine in obese subjects.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1992, Volume: 16, Issue:5

    Topics: Adult; Basal Metabolism; Body Temperature Regulation; Double-Blind Method; Female; Fluoxetine; Human

1992
Short-term use of fluoxetine in asymptomatic obese subjects with sleep-related hypoventilation.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1992, Volume: 16, Issue:10

    Topics: Adult; Apnea; Double-Blind Method; Female; Fluoxetine; Humans; Hypoventilation; Male; Middle Aged; O

1992
Fluoxetine increases insulin action in obese type II (non-insulin dependent) diabetic patients.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1992, Volume: 16 Suppl 4

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Double-Blind Method; Female; Fluoxetine; Glucose; Glu

1992
A randomized double-blind clinical trial of fluoxetine in obese diabetics.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1992, Volume: 16 Suppl 4

    Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind Method; Femal

1992
Fluoxetine therapy in obese diabetic and glucose intolerant patients.
    International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 1992, Volume: 16 Suppl 4

    Topics: Blood Glucose; Diabetes Mellitus; Double-Blind Method; Female; Fluoxetine; Glucose Tolerance Test; G

1992
Effect of serotonin re-uptake inhibition by fluoxetine on body weight and spontaneous food choice in obesity.
    International journal of obesity, 1991, Volume: 15, Issue:3

    Topics: Adult; Body Mass Index; Body Weight; Brain; Energy Intake; Female; Fluoxetine; Food Preferences; Hum

1991
Clinical studies with fluoxetine in obesity.
    The American journal of clinical nutrition, 1992, Volume: 55, Issue:1 Suppl

    Topics: Adult; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Weight Loss

1992
Fluoxetine's effect on weight loss in obese subjects.
    The American journal of clinical nutrition, 1991, Volume: 54, Issue:2

    Topics: Adolescent; Adult; Double-Blind Method; Fluoxetine; Humans; Middle Aged; Obesity; Time Factors; Weig

1991
A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge-eaters.
    The American journal of psychiatry, 1990, Volume: 147, Issue:7

    Topics: Adolescent; Adult; Attitude to Health; Behavior Therapy; Bulimia; Clinical Trials as Topic; Combined

1990
Use of fluoxetine, a selective serotonin-uptake inhibitor, in the treatment of obesity: a dose-response study (with a commentary by Michael Weintraub).
    International journal of obesity, 1989, Volume: 13, Issue:5

    Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Female; Fluoxetine; Humans; Male; Middle

1989
Use of a serotonin re-uptake inhibitor, fluoxetine, in the treatment of obesity.
    International journal of obesity, 1987, Volume: 11 Suppl 3

    Topics: Adolescent; Adult; Aged; Female; Fluoxetine; Humans; Male; Middle Aged; Obesity; Propylamines

1987
Fluoxetine-induced weight loss in overweight, nondepressed subjects.
    The American journal of psychiatry, 1986, Volume: 143, Issue:11

    Topics: Adolescent; Adult; Aged; Appetite; Body Weight; Clinical Trials as Topic; Double-Blind Method; Femal

1986

Other Studies

48 other studies available for fluoxetine and Obesity

ArticleYear
Effect of statins on the age of onset of age-related macular degeneration.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2023, Volume: 261, Issue:8

    Topics: Age of Onset; Female; Fluoxetine; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Macular De

2023
A nationwide pharmacovigilance investigation on trends and seriousness of adverse events induced by anti-obesity medication.
    Journal of global health, 2023, Sep-01, Volume: 13

    Topics: Cardiovascular Diseases; Cross-Sectional Studies; Female; Fluoxetine; Humans; Male; Obesity; Pharmac

2023
The antidepressant fluoxetine acts on energy balance and leptin sensitivity via BDNF.
    Scientific reports, 2018, 01-29, Volume: 8, Issue:1

    Topics: Adipose Tissue, White; Animals; Antidepressive Agents; Body Weight; Brain-Derived Neurotrophic Facto

2018
Body composition, biochemical, behavioral and molecular alterations in overfed rats after chronic exposure to SSRI.
    Behavioural brain research, 2019, 01-01, Volume: 356

    Topics: Animals; Behavior, Animal; Body Composition; Body Weight; Eating; Energy Metabolism; Fluoxetine; Hyp

2019
Short-term antidepressant treatment has long-lasting effects, and reverses stress-induced decreases in bone features in rats.
    Translational psychiatry, 2019, 01-16, Volume: 9, Issue:1

    Topics: Animals; Antidepressive Agents; Behavior, Animal; Bone Density; Disease Models, Animal; Fluoxetine;

2019
Influence of body mass index on the choice of therapy for depression and follow-up care.
    Obesity (Silver Spring, Md.), 2013, Volume: 21, Issue:3

    Topics: Adolescent; Adult; Aged; Antidepressive Agents; Body Mass Index; Choice Behavior; Cohort Studies; De

2013
Both body weight and BMI predicts improvement in symptom and functioning for patients with major depressive disorder.
    Journal of affective disorders, 2014, Volume: 161

    Topics: Adult; Antidepressive Agents, Second-Generation; Body Mass Index; Body Weight; Depressive Disorder,

2014
Sex-related differences in small intestinal transit and serotonin dynamics in high-fat-diet-induced obesity in mice.
    Experimental physiology, 2016, Volume: 101, Issue:1

    Topics: Animals; Carbolines; Diet, High-Fat; Female; Fluoxetine; Gastrointestinal Transit; Intestine, Small;

2016
Brain endocannabinoid system is involved in fluoxetine-induced anorexia.
    Nutritional neuroscience, 2008, Volume: 11, Issue:3

    Topics: Animals; Anorexia; Brain; Brain Chemistry; Cannabinoid Receptor Modulators; Corpus Striatum; Endocan

2008
Immunohistochemical localization of CB1 cannabinoid receptors in frontal cortex and related limbic areas in obese Zucker rats: effects of chronic fluoxetine treatment.
    Brain research, 2008, Oct-21, Volume: 1236

    Topics: Analysis of Variance; Animals; Cell Count; Disease Models, Animal; Dose-Response Relationship, Drug;

2008
Brain serotonin, psychoactive drugs, and effects on reproduction.
    Central nervous system agents in medicinal chemistry, 2009, Volume: 9, Issue:4

    Topics: Affect; Amphetamine-Related Disorders; Animals; Biological Clocks; Brain; Cognition Disorders; Depre

2009
A rare cause of syncope: cough.
    European review for medical and pharmacological sciences, 2012, Volume: 16 Suppl 1

    Topics: Antidepressive Agents, Second-Generation; Cough; Fluoxetine; Gastroesophageal Reflux; Humans; Male;

2012
Serotonin availability in rat colon is reduced during a Western diet model of obesity.
    American journal of physiology. Gastrointestinal and liver physiology, 2012, Aug-01, Volume: 303, Issue:3

    Topics: Animals; Colon; Constipation; Diet; Diet, High-Fat; Enterochromaffin Cells; Fluoxetine; Gastrointest

2012
Differential effects of chronic social stress and fluoxetine on meal patterns in mice.
    Appetite, 2013, Volume: 64

    Topics: Animals; Antidepressive Agents, Second-Generation; Chronic Disease; Corticosterone; Eating; Energy I

2013
Is fluoxetine an effective therapy for weight loss in obese patients?
    American family physician, 2003, Dec-15, Volume: 68, Issue:12

    Topics: Fluoxetine; Humans; Obesity; Selective Serotonin Reuptake Inhibitors

2003
A study of electrical conductance of meridian in the obese during weight reduction.
    The American journal of Chinese medicine, 2004, Volume: 32, Issue:3

    Topics: Adult; Body Mass Index; Case-Control Studies; Diet, Reducing; Electric Impedance; Exercise; Female;

2004
Effects of fluoxetine administration on regional galanin expression in obese Zucker rat hypothalamus.
    Nutritional neuroscience, 2004, Volume: 7, Issue:3

    Topics: Adipose Tissue; Animals; Body Composition; Body Weight; Eating; Fluoxetine; Galanin; Hypothalamus; M

2004
Fatal fluoxetine ingestion with postmortem blood concentrations.
    Clinical toxicology (Philadelphia, Pa.), 2005, Volume: 43, Issue:4

    Topics: Adult; Anticonvulsants; Antidepressive Agents, Second-Generation; Bradycardia; Child, Preschool; Dia

2005
Baseline predictors of success when comparing two treatments.
    Obesity research, 1994, Volume: 2, Issue:4

    Topics: Anti-Obesity Agents; Fluoxetine; Humans; Obesity; Predictive Value of Tests; Randomized Controlled T

1994
Fluoxetine alters mu opioid receptor expression in obese Zucker rat extrahypothalamic regions.
    The International journal of neuroscience, 2006, Volume: 116, Issue:3

    Topics: Animals; Brain; Cell Count; Disease Models, Animal; Fluoxetine; Gene Expression; Immunohistochemistr

2006
Inhibition of dopamine and norepinephrine reuptake produces additive effects on energy balance in lean and obese mice.
    Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2007, Volume: 32, Issue:4

    Topics: Animals; Behavior, Animal; Body Weight; Bupropion; Dopamine; Dose-Response Relationship, Drug; Drug

2007
Comparison of combinations of drugs for treatment of obesity: body weight and echocardiographic status.
    International journal of obesity (2005), 2007, Volume: 31, Issue:5

    Topics: Adult; Appetite Depressants; Body Mass Index; Drug Therapy, Combination; Fenfluramine; Fluoxetine; H

2007
[Pharmacotherapy for weight loss in patients with type 2 diabetes].
    Ugeskrift for laeger, 2007, Aug-13, Volume: 169, Issue:33

    Topics: Anti-Obesity Agents; Appetite Depressants; Cyclobutanes; Diabetes Mellitus, Type 2; Evidence-Based M

2007
Effects of fluoxetine administration on hypothalamic melanocortin system in obese Zucker rats.
    Neuropeptides, 2008, Volume: 42, Issue:3

    Topics: Agouti-Related Protein; alpha-MSH; Animals; Appetite Depressants; Body Weight; DNA Primers; Eating;

2008
Onset of menses in two adult patients with Prader-Willi syndrome treated with fluoxetine.
    Psychopharmacology bulletin, 1995, Volume: 31, Issue:2

    Topics: Adult; Age of Onset; Female; Fluoxetine; Follow-Up Studies; Gonadotropin-Releasing Hormone; Humans;

1995
Fluoxetine induced weight loss: a pilot study in postpartum women.
    The Israel journal of psychiatry and related sciences, 1995, Volume: 32, Issue:1

    Topics: Adult; Female; Fluoxetine; Humans; Obesity; Pilot Projects; Puerperal Disorders; Weight Loss

1995
Response to Roback et al.
    Obesity research, 1995, Volume: 3, Issue:2

    Topics: Adolescent; Adult; Fluoxetine; Humans; Obesity; Weight Loss

1995
Fluoxetine (Prozac) and other drugs for treatment of obesity.
    The Medical letter on drugs and therapeutics, 1994, Nov-25, Volume: 36, Issue:936

    Topics: Clinical Trials as Topic; Drug Therapy, Combination; Fenfluramine; Fluoxetine; Humans; Obesity; Phen

1994
[Fluoxetine and obesity].
    Minerva endocrinologica, 1993, Volume: 18, Issue:1

    Topics: Adolescent; Appetite; Combined Modality Therapy; Fluoxetine; Humans; Male; Obesity; Serotonin

1993
The influence of serotonergic neurotransmission on pituitary hormone release in obese and non-obese females.
    Acta endocrinologica, 1993, Volume: 128, Issue:4

    Topics: Adrenocorticotropic Hormone; Adult; Analysis of Variance; beta-Endorphin; Corticotropin-Releasing Ho

1993
[The effect of fluoxetine on insulin resistance in non diabetic obese patients].
    Revista medica de Chile, 1995, Volume: 123, Issue:8

    Topics: Adult; Antidepressive Agents, Second-Generation; Fluoxetine; Glucose Tolerance Test; Humans; Insulin

1995
The serotonergic agent fluoxetine reduces neuropeptide Y levels and neuropeptide Y secretion in the hypothalamus of lean and obese rats.
    Neuroscience, 1996, Volume: 72, Issue:2

    Topics: Animals; Arcuate Nucleus of Hypothalamus; Autoradiography; Blood Glucose; Body Weight; Eating; Fluox

1996
Serotonergic agents in the treatment of hypothalamic obesity syndrome: a case report.
    The International journal of eating disorders, 1996, Volume: 20, Issue:1

    Topics: Adult; Body Weight; Brain Damage, Chronic; Dose-Response Relationship, Drug; Fenfluramine; Fluoxetin

1996
Fluoxetine is a safer alternative to fenfluramine in the medical treatment of obesity.
    Archives of internal medicine, 1997, Jun-09, Volume: 157, Issue:11

    Topics: Appetite Depressants; Fenfluramine; Fluoxetine; Humans; Hypertension, Pulmonary; Obesity; Selective

1997
Comparison of the effects of sibutramine and other monoamine reuptake inhibitors on food intake in the rat.
    British journal of pharmacology, 1997, Volume: 121, Issue:8

    Topics: Animals; Cyclobutanes; Cyclohexanols; Eating; Fenfluramine; Fluoxetine; Male; Neurotransmitter Uptak

1997
Nutritional implications of xerostomia and rampant caries caused by serotonin reuptake inhibitors: a case study.
    Nutrition reviews, 1997, Volume: 55, Issue:10

    Topics: Adult; Antidepressive Agents; Dental Caries; Diet; Female; Fenfluramine; Fluoxetine; Humans; Obesity

1997
After fen-phen.
    Newsweek, 1997, Sep-29, Volume: 130, Issue:13

    Topics: Antidepressive Agents, Second-Generation; Appetite Depressants; Consumer Product Safety; Fenfluramin

1997
Decreased plasma leptin levels in lean and obese Zucker rats after treatment with the serotonin reuptake inhibitor fluoxetine.
    Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme, 1999, Volume: 31, Issue:6

    Topics: Animals; Eating; Fluoxetine; Leptin; Male; Obesity; Proteins; Rats; Rats, Zucker; Selective Serotoni

1999
[Disorder of eating behavior and comorbid syndromes in obesity and methods of their correction].
    Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2000, Volume: 100, Issue:12

    Topics: Adult; Depressive Disorder; Feeding Behavior; Female; Fluoxetine; Humans; Obesity; Selective Seroton

2000
[The role of pharmacotherapy for treatment of obesity in adults].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2000, Volume: 9, Issue:53

    Topics: Adult; Animals; Anti-Obesity Agents; Chlorphentermine; Cyclobutanes; Dexfenfluramine; Dopamine Agoni

2000
Accelerated weight loss after treating refractory depression with fluoxetine plus topiramate: possible mechanisms of action?
    Canadian journal of psychiatry. Revue canadienne de psychiatrie, 2001, Volume: 46, Issue:3

    Topics: Adult; Antidepressive Agents, Second-Generation; Appetite; Depressive Disorder; Drug Therapy, Combin

2001
Conditional deletion of brain-derived neurotrophic factor in the postnatal brain leads to obesity and hyperactivity.
    Molecular endocrinology (Baltimore, Md.), 2001, Volume: 15, Issue:10

    Topics: Animals; Anxiety; Body Weight; Brain; Brain-Derived Neurotrophic Factor; Fasting; Fluoxetine; Gene D

2001
Serotonergic activation rescues reproductive function in fasted mice: does serotonin mediate the metabolic effects of leptin on reproduction?
    Biology of reproduction, 2002, Volume: 66, Issue:6

    Topics: Animals; Body Weight; Diabetes Mellitus; Eating; Estrous Cycle; Fasting; Female; Fertility; Fluoxeti

2002
Effects of fluoxetine administration on neuropeptide y and orexins in obese zucker rat hypothalamus.
    Obesity research, 2002, Volume: 10, Issue:6

    Topics: Adipocytes; Adipose Tissue; Animals; Blood Glucose; Body Composition; Body Weight; Carrier Proteins;

2002
Ineffectiveness of parenteral fluoxetine or RU-486 to alter long-term food intake, body weight or body composition of genetically obese mice.
    The Journal of pharmacology and experimental therapeutics, 1990, Volume: 255, Issue:3

    Topics: Animals; Body Composition; Body Weight; Drug Administration Schedule; Eating; Female; Fluoxetine; In

1990
Fluoxetine for depression.
    The Medical letter on drugs and therapeutics, 1988, Apr-22, Volume: 30, Issue:764

    Topics: Antidepressive Agents, Tricyclic; Depressive Disorder; Fluoxetine; Humans; Obesity; Obsessive-Compul

1988
Fluoxetine-induced weight loss in overweight non-depressed humans.
    International journal of obesity, 1987, Volume: 11 Suppl 3

    Topics: Adolescent; Adult; Depressive Disorder; Dietary Carbohydrates; Female; Fluoxetine; Humans; Male; Mid

1987
Safety of fluoxetine in the treatment of obesity.
    International journal of obesity, 1987, Volume: 11 Suppl 3

    Topics: Drug Interactions; Fluoxetine; Heart; Humans; Lipidoses; Liver; Obesity; Phospholipids; Propylamines

1987